Structural highlights
Publication Abstract from PubMed
A four step process of high quality modelling of existing data, deconstruction, identification of replacement cores and an innovative synthetic re-growth strategy led to the rapid discovery of a novel oral series of PI3K delta inhibitors with promising selectivity and excellent in vivo characteristics.
Evolution of a novel orally bioavailable series of PI3K delta inhibitors from an inhaled lead for the treatment of respiratory disease.,Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Perez D, Peace S, Rowland P, Tame C, Uddin S, Vitulli G, Wellaway N J Med Chem. 2016 Jul 18. PMID:27429068[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Amour A, Barton N, Cooper AW, Inglis G, Jamieson C, Luscombe CN, Perez D, Peace S, Rowland P, Tame C, Uddin S, Vitulli G, Wellaway N. Evolution of a novel orally bioavailable series of PI3K delta inhibitors from an inhaled lead for the treatment of respiratory disease. J Med Chem. 2016 Jul 18. PMID:27429068 doi:http://dx.doi.org/10.1021/acs.jmedchem.6b00799
